RxDoctor Payments Data

Robert Wilson, DO

Family Medicine · Pflugerville, TXNPI 1538783832

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 45 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$288
  • AstraZeneca$158
  • Exact Sciences$151
  • Novocure Inc.$132
  • GSK$68
  • Lilly USA, LLC$66
  • plus $191 from 6 others

What the payments were for

  • Food & beverage$1,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,982
Medicare patients
205
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab14$114,813
MounjaroTirzepatide90$105,484
OzempicSemaglutide71$76,203
RybelsusSemaglutide49$52,005
JardianceEmpagliflozin46$48,570
TrulicityDulaglutide19$25,421
JanuviaSitagliptin Phosphate17$19,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,543
EliquisApixaban13$12,048
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,277
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,817
BelsomraSuvorexant13$7,136
SynthroidLevothyroxine Sodium15$1,908
Gabapentin107$1,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$66$130,906109 claims
Novo NordiskOzempic, Rybelsus$288$128,208120 claims
GSKTrelegy Ellipta, Anoro Ellipta$68$25,36040 claims
AstraZenecaBreztri Aerosphere$158$10,27711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Pflugerville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →